Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Pyrotinib in Combination With Fulvestrant in Patients With HER2 Positive HR-Positive Metastatic Breast Cancer

, phase II clinical trial to evaluate the efficacy and safety of erlotinib in combination with fulvestrant in patients with human epidermal growth factor receptor 2 (HER2) positivehormone receptor

metastasis
hormone therapy
epidermal growth factor receptor
estrogen receptor
immunological adjuvant
  • 9 views
  • 27 Jan, 2021
  • 2 locations
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib

randomized phase 3 study clearly demonstrated the superiority of osimertinib compared with erlotinib or gefitinib in EGFR mutated nonpretreated NSCLC (median PFS of 18.9 months versus 10.2 months).

gefitinib
epidermal growth factor receptor
egfr t790m
kinase inhibitor
follicle stimulating hormone
  • 6 views
  • 23 Jan, 2021
  • 15 locations
Prospective Monocentric Clinical-biological Database

) derived tumors of patients reported that the response rate of PDX to certain drugs (gemcitabine, erlotinib ...) used clinically was similar to the response rates of patients enrolled in clinical studies

gemcitabine
pancreatic adenocarcinoma
cancer chemotherapy
tumor cells
erlotinib
  • 1 views
  • 28 Jun, 2021
  • 2 locations
Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC

To investigate the curative effect between Pemetrexed/Cisplatin and Pemetrexed/Cisplatin intercalating Gefitinib Treating EGFR Wild NSCLC

pemetrexed
secondary malignant neoplasm of liver
metastasis
chemoradiotherapy
gefitinib
  • 0 views
  • 22 Jan, 2021
  • 1 location
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

cytarabine
imatinib
fludarabine
ifosfamide
cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III

The use of induction chemotherapy is feasible and effective. It is also logistically beneficial for decreasing micrometastases and radiation-related toxicity by decreasing tumor burden before definite locoregional concurrent therapy. Previously the investigators conducted several phase II study of IP chemotherapy in advanced NSCLC and demonstrated that IP chemotherapy has a …

kidney function test
measurable disease
epinephrine
neutrophil count
serum bilirubin level
  • 1 views
  • 07 Nov, 2020
  • 1 location
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene

Current chemotherapy for advanced non-small cell lung cancer, not amenable for curative local treatment (surgery or chemoradiotherapy), has a modest life-prolonging effect and can improve quality of life. There is however no potential for long-term cure for these patients. Chemotherapy also produces variable and often significant toxicity. Current retrospective evidence …

adjuvant chemotherapy
gemcitabine
cancer
platelet count
serum bilirubin level
  • 27 views
  • 07 Nov, 2020
  • 1 location
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC Prospective Study

This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.

gefitinib
icotinib
chemotherapy regimen
cancer chemotherapy
cancer
  • 0 views
  • 27 Jul, 2021
  • 6 locations
Metastatic Advanced Pancreas Sorafenib

This is multicentre, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Subjects will be randomized in a 1:1 ratio to receive gemcitabine/cisplatin in combination with Sorafenib (arm A) or gemcitabine/cisplatin alone (arm B), as first-line chemotherapy.

  • 33 views
  • 07 Nov, 2020
  • 1 location
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical …

  • 0 views
  • 13 May, 2021
  • 20 locations